微球
类风湿性关节炎
医学
关节炎
内科学
化学工程
工程类
作者
Shudan Wang,Tian Yin,Yaxin Deng,Tian Yin,Haibing He,Tian Yin,Tian Yin,Mohamed El‐Shazly,Qian Zhang
标识
DOI:10.1016/j.ijpharm.2024.124414
摘要
Bulleyaconitine A (BLA) is a promising candidate for treating rheumatoid arthritis (RA) with diverse pharmacological activities, including anti-inflammatory, analgesic and bone repair. Herein, the long-acting bulleyaconitine A microspheres (BLA-MS) were developed to treat RA comprehensively by forming drug reservoirs in joint cavities. The BLA-MS were prepared by emulsion/solvent evaporation method. The particle size and distribution were assessed by SEM. The crystalline state was investigated by DSC and PXRD. The drug loading (DL), encapsulation efficiency (EE) and cumulative release in vitro were determined by HPLC. The DL and EE were 23.93 ± 0.38 % and 95.73 ± 1.56 % respectively, and the cumulative release was up to 69 days with a stable release curve. The pharmacodynamic results in collagen induced arthritis (CIA) rats showed a noticeable reduction in paw thickness (5.66 ± 0.32 mm), and the decreasing expression level of PGE
科研通智能强力驱动
Strongly Powered by AbleSci AI